Kyndryl Class Action Deadline Set for April 13 as Audit Review Sparks Investigation

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Kyndryl faces securities fraud investigation after disclosing audit review of cash management and internal controls. Stock fell 50%; class action deadline set for April 13.

Kyndryl Class Action Deadline Set for April 13 as Audit Review Sparks Investigation

Law firm Faruqi & Faruqi, LLP is investigating potential securities fraud allegations against Kyndryl Holdings, Inc. following the company's disclosure on February 9, 2026 that its Audit Committee is conducting a comprehensive review of cash management practices and internal control procedures. The review was initiated after the company received enforcement document requests from the Securities and Exchange Commission.

Kyndryl's subsequent announcements have outlined significant accounting concerns, with the company indicating it expects to identify material weaknesses in internal controls spanning multiple fiscal periods. The disclosure prompted the company to delay its quarterly earnings report filing while the review continues. The stock has declined approximately 50% since the initial announcement, triggering investor concerns regarding the company's financial reporting accuracy and governance practices.

Investors who purchased Kyndryl securities between August 7, 2024 and February 9, 2026 retain the opportunity to seek lead plaintiff status in the proposed class action litigation. The deadline for filing such requests is April 13, 2026. Interested parties are encouraged to consult with legal counsel regarding their eligibility and potential claims under securities laws.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 14

Related Coverage

GlobeNewswire Inc.

Gemini Space Station Faces Class Action Lawsuit Over IPO Misstatements

Class action lawsuit filed against Gemini Space Station for alleged IPO misstatements regarding crypto platform viability and international expansion. Application deadline: May 18, 2026.

ENPHGEMI
GlobeNewswire Inc.

Immutep Stock Plummets 82.6% After Failed Phase III Trial, Sparking Lawsuit

Immutep's $IMMP stock crashed following discontinued Phase III trial for eftilagimod alfa. Rosen Law Firm launches investigation into potential securities claims and class action lawsuit.

IMMP
GlobeNewswire Inc.

Lufax Investors Face May 2026 Deadline in Securities Fraud Class Action

Rosen Law Firm filed securities class action against $LU alleging false statements on internal controls and financials. Investors have until May 20, 2026 to claim lead plaintiff status.

LU
GlobeNewswire Inc.

Inovio Investors Face April 7 Deadline in Securities Class Action Over Alleged Misstatements

Rosen Law Firm alerts $INO investors of April 7, 2026 deadline to join class action over alleged false statements regarding manufacturing and regulatory prospects.

INO
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS